[go: up one dir, main page]

AR052339A1 - Formulaciones terapeuticas del factor de crecimiento queratinocitico - Google Patents

Formulaciones terapeuticas del factor de crecimiento queratinocitico

Info

Publication number
AR052339A1
AR052339A1 ARP050105231A ARP050105231A AR052339A1 AR 052339 A1 AR052339 A1 AR 052339A1 AR P050105231 A ARP050105231 A AR P050105231A AR P050105231 A ARP050105231 A AR P050105231A AR 052339 A1 AR052339 A1 AR 052339A1
Authority
AR
Argentina
Prior art keywords
growth factor
queratinocitic
therapeutic formulations
lyophilized
keratinocyte growth
Prior art date
Application number
ARP050105231A
Other languages
English (en)
Inventor
Michael J Treuheit
Vasumathi Dharmavaram
Judith Purtell
Suzanne E Roy
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR052339A1 publication Critical patent/AR052339A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulaciones estables y duraderas del factor de crecimiento queratinocítico liofilizado y métodos para elaborar una composicion liofilizada que comprende el factor de crecimiento queratinocítico. Reivindicacion 1: Una composicion del factor de crecimiento queratinocítico [KGF, por sus siglas en inglés] liofilizado, que la comprende solucion estabilizadora de histidina, un agente de carga, un azucar y un surfactante.
ARP050105231A 2004-12-15 2005-12-14 Formulaciones terapeuticas del factor de crecimiento queratinocitico AR052339A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63621004P 2004-12-15 2004-12-15
US11/302,033 US8304387B2 (en) 2004-12-15 2005-12-12 Therapeutic formulations of keratinocyte growth factor

Publications (1)

Publication Number Publication Date
AR052339A1 true AR052339A1 (es) 2007-03-14

Family

ID=36337531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105231A AR052339A1 (es) 2004-12-15 2005-12-14 Formulaciones terapeuticas del factor de crecimiento queratinocitico

Country Status (27)

Country Link
US (1) US8304387B2 (es)
EP (1) EP1827483B1 (es)
JP (1) JP5201992B2 (es)
KR (1) KR101283736B1 (es)
CN (1) CN101084008B (es)
AR (1) AR052339A1 (es)
AU (1) AU2005317166B2 (es)
BR (1) BRPI0519070A2 (es)
CA (1) CA2589889C (es)
CR (1) CR9246A (es)
DK (1) DK1827483T3 (es)
EA (1) EA013369B1 (es)
ES (1) ES2504441T3 (es)
HR (1) HRP20140926T1 (es)
IL (1) IL183435A (es)
MX (1) MX2007006822A (es)
MY (1) MY145638A (es)
NO (1) NO20073629L (es)
NZ (1) NZ555503A (es)
PL (1) PL1827483T3 (es)
PT (1) PT1827483E (es)
RS (1) RS53548B1 (es)
SI (1) SI1827483T1 (es)
TW (1) TWI351966B (es)
UA (1) UA88497C2 (es)
WO (1) WO2006065861A2 (es)
ZA (1) ZA200706095B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1827483T3 (pl) 2004-12-15 2014-12-31 Swedish Orphan Biovitrum Ab Publ Formulacje terapeutyczne czynnika wzrostu keratynocytów
US20090186805A1 (en) * 2006-07-06 2009-07-23 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN107041948A (zh) * 2009-01-21 2017-08-15 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
IT1396020B1 (it) * 2009-10-16 2012-11-09 Fitologica Srl Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico.
CN102675449B (zh) * 2011-03-17 2016-06-08 重庆富进生物医药有限公司 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途
CN102379838B (zh) * 2011-11-02 2013-06-12 广州舒泰生物技术有限公司 一种舒缓静颜化妆品的制备方法及应用
US20140287995A1 (en) * 2011-11-02 2014-09-25 The University Of Chicago Stable pharmaceutical formulations of growth factor peptides
US20150126433A1 (en) * 2012-04-25 2015-05-07 University Of Cincinnati Growth factors for the treatment of mycobacterial infection
JP6387392B2 (ja) 2013-03-15 2018-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子ポリペプチド製剤
WO2015148444A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Lyophilized factor ix formulations
CN108359634A (zh) * 2018-02-02 2018-08-03 江阴司特易生物技术有限公司 一种饲养细胞蛋白复合物及其应用
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
SG11202113022UA (en) * 2019-06-24 2021-12-30 Hangzhou Dac Biotech Co Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
CN110339345B (zh) * 2019-07-30 2022-11-29 重庆派金生物科技有限公司 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof
CN119632934A (zh) * 2025-02-19 2025-03-18 杭州熙岭生物科技有限公司 一种kgf-2组合物的冻干粉及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) * 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
ES2153816T3 (es) * 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
DE10399015I1 (de) * 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
BR9407035A (pt) * 1993-06-29 1996-03-12 Chiron Corp Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE69530404T2 (de) 1994-10-13 2003-11-13 Amgen Inc., Thousand Oaks Analogen des keratinozytenwachstumfaktors
ATE237633T1 (de) 1994-10-13 2003-05-15 Amgen Inc Analogen des keratinozytenwachstumfaktors
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
PT1012186E (pt) * 1996-12-06 2002-12-31 Amgen Inc Utilizacao de produto(s) da proteina kgf e de produto(s) da proteina glp-2 para a preparacao de um medicamento
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
KR20010033484A (ko) * 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
CN1359299A (zh) * 1999-06-02 2002-07-17 人类基因组科学公司 角质细胞生长因子－2制剂
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
PL1827483T3 (pl) 2004-12-15 2014-12-31 Swedish Orphan Biovitrum Ab Publ Formulacje terapeutyczne czynnika wzrostu keratynocytów

Also Published As

Publication number Publication date
CA2589889A1 (en) 2006-06-22
TW200635603A (en) 2006-10-16
AU2005317166B2 (en) 2009-09-10
MX2007006822A (es) 2007-07-24
AU2005317166A1 (en) 2006-06-22
WO2006065861A3 (en) 2006-08-17
DK1827483T3 (da) 2014-10-06
HRP20140926T1 (hr) 2014-11-07
SI1827483T1 (sl) 2014-11-28
KR101283736B1 (ko) 2013-07-08
NZ555503A (en) 2010-01-29
CN101084008B (zh) 2013-04-10
CA2589889C (en) 2013-07-30
MY145638A (en) 2012-03-15
IL183435A (en) 2010-11-30
HK1115298A1 (en) 2008-11-28
RS53548B1 (sr) 2015-02-27
IL183435A0 (en) 2007-09-20
WO2006065861A2 (en) 2006-06-22
JP5201992B2 (ja) 2013-06-05
PL1827483T3 (pl) 2014-12-31
EP1827483A2 (en) 2007-09-05
PT1827483E (pt) 2014-09-25
US20060128622A1 (en) 2006-06-15
EA013369B1 (ru) 2010-04-30
ES2504441T3 (es) 2014-10-08
UA88497C2 (ru) 2009-10-26
US8304387B2 (en) 2012-11-06
EA200701293A1 (ru) 2008-02-28
EP1827483B1 (en) 2014-07-02
CN101084008A (zh) 2007-12-05
CR9246A (es) 2007-10-23
JP2008524229A (ja) 2008-07-10
KR20070093977A (ko) 2007-09-19
NO20073629L (no) 2007-09-10
ZA200706095B (en) 2008-09-25
TWI351966B (en) 2011-11-11
BRPI0519070A2 (pt) 2008-12-23

Similar Documents

Publication Publication Date Title
AR052339A1 (es) Formulaciones terapeuticas del factor de crecimiento queratinocitico
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR052545A1 (es) Suspension no acuosa inyectable
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
CL2007001185A1 (es) Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
AR033903A1 (es) Una composicion de insulina modificada quimicamente para la administracion pulmonar
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
TW200806317A (en) Methods for reducing protein aggregation
BRPI0514474A (pt) multiparticulados
AR064614A1 (es) Producto combinado par controlar parasitos en animales
TNSN08391A1 (en) Lyophilized therapeutic peptibody formulations
MY167123A (en) Conveniently implantable sustained release drug compositions
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
ECSP088240A (es) Composición de trazodona para administración una vez por día
AR109263A2 (es) Composición que comprende moxidectina
ECSP045065A (es) Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
WO2006081435A3 (en) Method of providing readily available cellular material derived from cord blood, and a composition thereof
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
AR061802A1 (es) Composicion que tiene una actividad que previene la germinacion, procedimientos para obtener dichas composiciones y uso de las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure